IT1226800B
(it)
*
|
1988-09-16 |
1991-02-19 |
Prodotti Formenti |
Composizioni farmaceutiche orali contenenti sali di destrorfano.
|
US5334618A
(en)
*
|
1991-04-04 |
1994-08-02 |
The Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
US5506231A
(en)
*
|
1989-03-31 |
1996-04-09 |
The Children's Medical Center Corporation |
Treatment of aids dementia, myelopathy and blindness
|
WO1991002810A1
(en)
*
|
1989-08-09 |
1991-03-07 |
The Children's Medical Center Corporation |
Nmda oxidizing agents for protecting neurons from injury
|
WO1991002523A1
(en)
*
|
1989-08-17 |
1991-03-07 |
The Children's Medical Center Corporation |
Glutamatergic amino acid agonists and antagonists
|
PT95069B
(pt)
*
|
1989-08-24 |
1997-10-31 |
Searle & Co |
Processo para a preparacao de (+)-isomeros de derivados de endoetano/endoetanoepoximofinano, uteis como agentes anti-tussicos
|
EP0424179A3
(en)
*
|
1989-10-20 |
1991-12-27 |
John William Olney |
Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
|
US5013540A
(en)
*
|
1989-11-30 |
1991-05-07 |
Board Of Regents, The University Of Texas System |
Using NMDA receptor antagonists to reduce damage due to laser treatment
|
US5229394A
(en)
*
|
1990-07-30 |
1993-07-20 |
Arch Development Corporation |
Method for treatment of amyotrophic lateral sclerosis comprising administration of dmp
|
US5089517A
(en)
*
|
1990-08-03 |
1992-02-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neuroprotection by indolactam v and derivatives thereof
|
US5145862A
(en)
*
|
1990-08-16 |
1992-09-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Method of resisting neurodegenerative disorders
|
US5455279A
(en)
*
|
1991-04-19 |
1995-10-03 |
The Children's Medical Center Corporation |
Regimen method of mediating neuronal damage using nitroglycerine
|
US5614560A
(en)
*
|
1991-04-04 |
1997-03-25 |
Children's Medical Center Corporation |
Method of preventing NMDA receptor-mediated neuronal damage
|
US6071876A
(en)
*
|
1991-04-19 |
2000-06-06 |
Children's Medical Center Corporation |
Method of preventing NMDA receptor complex-mediated neuronal damage
|
EP0581856B1
(en)
*
|
1991-04-19 |
1999-07-14 |
The Children's Medical Center Corporation |
Method of preventing nmda receptor complex-mediated neuronal damage
|
EP0531105B1
(en)
*
|
1991-09-03 |
1997-04-16 |
Carter-Wallace, Inc. |
Use of felbamate for the manufacture of a medicament for the treatment of neuropsychopharmacological disorders
|
SG80535A1
(en)
|
1991-09-06 |
2001-05-22 |
Mcneilab Inc |
Composition comprising a tramadol material and acetaminophen and its use
|
JPH07505908A
(ja)
*
|
1992-09-28 |
1995-06-29 |
マックセチーニ、マリア ルイザ |
Nmda受容体のアロステリックモジュレーター
|
US5854217A
(en)
*
|
1992-09-28 |
1998-12-29 |
Bearsden Bio, Inc. |
Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
|
TW264473B
(ja)
*
|
1993-01-06 |
1995-12-01 |
Hoffmann La Roche |
|
USRE39300E1
(en)
|
1993-01-28 |
2006-09-19 |
Virginia Commonwealth University Medical College Of Virginia |
Inhibiting the development of tolerance to and/or dependence on an addictive substance
|
US5321012A
(en)
*
|
1993-01-28 |
1994-06-14 |
Virginia Commonwealth University Medical College |
Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
|
CA2115792C
(en)
*
|
1993-03-05 |
2005-11-01 |
David J. Mayer |
Method for the treatment of pain
|
JP3348230B2
(ja)
*
|
1995-03-03 |
2002-11-20 |
アルゴス ファーマシューティカル コーポレーション |
尿失禁の治療用のデキシトルメトルファン又はデキシトルオルファンの使用
|
US5935606A
(en)
*
|
1995-07-31 |
1999-08-10 |
Sagen; Jaqueline |
Reversing excitotoxic CNS damage by cellular implantation
|
GB9522176D0
(en)
*
|
1995-10-30 |
1996-01-03 |
Iaf Biochem Int |
Morphinan derivatives having neuroprotective activity
|
US6017903A
(en)
|
1996-09-27 |
2000-01-25 |
Guilford Pharmaceuticals Inc. |
Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
|
US5824662A
(en)
|
1996-09-27 |
1998-10-20 |
Guilford Pharmaceuticals Inc. |
Treatment of global and focal ischemia using naaladase inhibitors
|
US6277825B1
(en)
|
1996-07-22 |
2001-08-21 |
University Of Utah Research Foundation |
Use of conantokins for treating pain
|
US6172041B1
(en)
|
1996-07-22 |
2001-01-09 |
University Of Utah Research Foundation |
Use of conantokins
|
JP2001507924A
(ja)
|
1996-07-22 |
2001-06-19 |
ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション |
コナントキン類
|
JP2002514184A
(ja)
|
1996-09-27 |
2002-05-14 |
ギルフォード ファーマスーティカルズ インコーポレイテッド |
Naaladアーゼ組成物ならびに動物におけるグルタメート異常を治療する方法および神経活性をもたらす方法
|
GB9706753D0
(en)
*
|
1997-04-03 |
1997-05-21 |
Pharmacia & Upjohn Spa |
Aralkoxy-morphinan derivatives
|
PL341309A1
(en)
*
|
1997-12-22 |
2001-04-09 |
Euro Celtique |
Method of preventing overdosage of opioidic preparations
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
US6277384B1
(en)
|
1997-12-22 |
2001-08-21 |
Euro-Celtique S.A. |
Opioid agonist/antagonist combinations
|
PT1255547E
(pt)
|
2000-02-08 |
2008-11-24 |
Euro Celtique Sa |
Composições de libertação controlada contendo agonistas e antagonistas opióides
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
US6399574B1
(en)
|
2000-03-22 |
2002-06-04 |
University Of Utah Research Foundation |
Use of conantokins
|
US20020013331A1
(en)
*
|
2000-06-26 |
2002-01-31 |
Williams Robert O. |
Methods and compositions for treating pain of the mucous membrane
|
CN1525851A
(zh)
|
2001-05-11 |
2004-09-01 |
������ҩ������˾ |
抗滥用阿片样物质控释剂型
|
PT1416842E
(pt)
*
|
2001-07-18 |
2009-03-31 |
Euro Celtique Sa |
Composições farmacêuticas de oxicodona e naloxona
|
PL367427A1
(en)
|
2001-08-06 |
2005-02-21 |
Euro-Celtique S.A. |
Opioid agonist formulations with releasable and sequestered antagonist
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
MXPA04009713A
(es)
|
2002-04-05 |
2005-01-11 |
Euro Celtique Sa |
Preparacion farmaceutica que contiene oxicodona y naloxona.
|
TWI326214B
(en)
*
|
2002-07-17 |
2010-06-21 |
Avanir Pharmaceuticals Inc |
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
|
JP2006502188A
(ja)
*
|
2002-09-17 |
2006-01-19 |
ニューヨーク ユニバーシティ |
年齢関連記憶欠陥(aami)、中程度認識欠陥(mci)、および痴呆を細胞周期インヒビターで処置する方法
|
DK1551372T3
(en)
*
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
MY135852A
(en)
*
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
AU2005244852B2
(en)
*
|
2004-05-12 |
2011-09-22 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods related to the treatment of neurodegenerative and inflammatory conditions
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
EP1702558A1
(en)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
WO2007092329A2
(en)
*
|
2006-02-03 |
2007-08-16 |
Avanir Pharmaceuticals |
Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
|
WO2007149438A2
(en)
*
|
2006-06-19 |
2007-12-27 |
Alpharma, Inc. |
Pharmaceutical compositions
|
JP5592790B2
(ja)
*
|
2007-08-06 |
2014-09-17 |
トリニティ ラボラトリーズ インコーポレイテッド |
慢性疼痛およびニューロパシーに関連する疼痛を治療する医薬組成物
|
US20110251229A1
(en)
*
|
2007-10-30 |
2011-10-13 |
The Regents Of The University Of Colorado |
(+)-opioids and methods of use
|
WO2009088673A2
(en)
*
|
2007-12-17 |
2009-07-16 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
*
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
PE20110422A1
(es)
*
|
2008-07-07 |
2011-07-01 |
Euro Celtique Sa |
Composicion farmaceutica que comprende antagonistas opioides
|
MY152279A
(en)
|
2009-03-10 |
2014-09-15 |
Euro Celtique Sa |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
UA116567C2
(uk)
|
2013-07-23 |
2018-04-10 |
Євро-Селтік С.А. |
Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
|
EP3200828B1
(en)
|
2014-10-03 |
2020-08-12 |
Lachesis Biosciences Limited |
Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
|
KR102491214B1
(ko)
|
2016-07-04 |
2023-01-26 |
아바니르 파마슈티컬스, 인코포레이티드 |
중수소화 덱스트로메토르판의 합성 방법
|